Havemeyer Place LP Takes $846,000 Position in Halozyme Therapeutics, Inc. $HALO

Havemeyer Place LP acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 12,576 shares of the biopharmaceutical company’s stock, valued at approximately $846,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Pinebridge Investments LLC bought a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $894,000. Prudential PLC increased its position in shares of Halozyme Therapeutics by 79.3% during the fourth quarter. Prudential PLC now owns 70,250 shares of the biopharmaceutical company’s stock valued at $4,728,000 after purchasing an additional 31,077 shares during the period. Vise Technologies Inc. bought a new stake in Halozyme Therapeutics in the fourth quarter valued at $500,000. Daiwa Securities Group Inc. grew its position in Halozyme Therapeutics by 45.3% in the fourth quarter. Daiwa Securities Group Inc. now owns 19,394 shares of the biopharmaceutical company’s stock valued at $1,305,000 after acquiring an additional 6,049 shares during the period. Finally, State of Wyoming grew its position in Halozyme Therapeutics by 551.1% in the fourth quarter. State of Wyoming now owns 7,247 shares of the biopharmaceutical company’s stock valued at $488,000 after acquiring an additional 6,134 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $70.73 on Tuesday. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The firm has a market cap of $8.39 billion, a P/E ratio of 25.44, a P/E/G ratio of 0.30 and a beta of 0.88. The business’s fifty day moving average is $66.94 and its two-hundred day moving average is $68.73. Halozyme Therapeutics, Inc. has a 52 week low of $51.06 and a 52 week high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. The company had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The business’s revenue was up 42.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities research analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $67.58, for a total value of $1,351,600.00. Following the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $51,886,572.40. The trade was a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $66.21, for a total value of $107,591.25. Following the completion of the transaction, the director directly owned 43,669 shares in the company, valued at approximately $2,891,324.49. This represents a 3.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 93,250 shares of company stock worth $6,299,746. Insiders own 2.50% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on HALO. Morgan Stanley lowered their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. UBS Group reiterated a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Wells Fargo & Company upped their price target on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. Finally, HC Wainwright upped their price target on Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $81.60.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.